Board meeting on 6 November 2026 to consider and approve unaudited standalone and consolidated results
Kilitch Drugs (India) Ltd has told the exchanges that its Board of Directors will meet on Friday, 6 November 2026.
By ScoutQuest · · 2 min read
- Board Meeting Date
- Friday, 6 November 2026
- Results Period
- quarter and half year ended 30 September 2026
- Trading Window Closure
- closed with effect from 1 October 2026; re-opens 48 hours after results are disclosed
What was announced
Kilitch Drugs (India) Ltd has informed BSE and NSE that a meeting of its Board of Directors will be held on Friday, 6 November 2026. The board will consider and approve the unaudited Financial Results (Standalone and Consolidated) of the company for the quarter and half year ended 30 September 2026.
Trading window
- The trading window has been closed with effect from 1 October 2026.
- It will re-open 48 hours after the financial results are disclosed to the stock exchanges.
- During a closed trading window, designated persons and insiders covered by the company's insider trading code cannot buy or sell the company's shares.
What the two sets of results mean
- Standalone results show the performance of the company on its own.
- Consolidated results show the performance of the company together with its subsidiaries.
- The quarter ended 30 September 2026 is the second quarter of the financial year; the half year covers the six months from 1 April 2026 to 30 September 2026.
Why investors track this
A board meeting called to approve quarterly and half-yearly results is a scheduled event in the listed-company calendar. The numbers approved at the meeting will show how the business performed in the July to September 2026 quarter and in the April to September 2026 half year.
What to look at when the results are published
- Revenue and profit for the quarter and for the half year.
- The same figures for the corresponding period a year earlier, to judge the direction of the business.
- How the standalone and consolidated numbers differ, which shows the contribution of the subsidiaries.
Key date on the calendar
The Board meets on Friday, 6 November 2026. The results approved at that meeting are the next substantive update from the company.
Also from Kilitch Drugs India
EGM on 16 Nov 2026 to vote on sale of entire stake in Ethiopian subsidiary, debt conversion, 2 director appointments
23 Oct 2026
Kilitch Drugs to divest Ethiopian subsidiary Kilitch Estro Biotech to HarmeeCare for US$14 million; plans new Pen facility
23 Oct 2026
Board approves divestment of 100% stake in Ethiopian material subsidiary, conversion of INR 57.00 Crores debt
23 Oct 2026
More numbers
- Trading window re-opening period after results disclosure48 hours
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.